Why Did SoundHound AI Stock Go Up?
SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…
Buy
77
CSPCY Quote, Financials, Valuation and Earnings
Last price:
$4.94
Seasonality move
:
-3.51%
Day range:
$4.94 - $4.94
52-week range:
$2.15 - $5.83
Dividend yield:
2.49%
P/E ratio:
23.23x
P/S ratio:
3.95x
P/B ratio:
17.31x
Volume:
--
Avg. volume:
6.4K
1-year change:
122.52%
Market cap:
$14.1B
Revenue:
$4B
EPS (TTM):
$0.19
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, CSPC Pharmaceutical Group Ltd. has -- downside to fair value with a price target of -- per share.
CSPCY vs. S&P 500
-
Over the past 5 trading days, CSPC Pharmaceutical Group Ltd. has underperformed the S&P 500 by -2.57% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
CSPC Pharmaceutical Group Ltd. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
CSPC Pharmaceutical Group Ltd. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter CSPC Pharmaceutical Group Ltd. reported revenues of $964.2M.
Earnings Growth
-
CSPC Pharmaceutical Group Ltd. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter CSPC Pharmaceutical Group Ltd. reported earnings per share of $0.07.
Enterprise value:
13.8B
EV / Invested capital:
--
Price / LTM sales:
3.95x
EV / EBIT:
23.64x
EV / Revenue:
3.84x
PEG ratio (5yr expected):
--
EV / Free cash flow:
31.80x
Price / Operating cash flow:
32.72x
Enterprise value / EBITDA:
17.77x
Gross Profit (TTM):
$2.4B
Return On Assets:
9.96%
Net Income Margin (TTM):
14.83%
Return On Equity:
12.37%
Return On Invested Capital:
12.94%
Operating Margin:
21.36%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $4.5B | -- | $4.2B | -- | $964.2M | |
| Gross Profit | $3.2B | -- | $3B | -- | $646.8M | |
| Operating Income | $976.5M | -- | $943.5M | -- | $205.9M | |
| EBITDA | $1.1B | -- | $1B | -- | $247.8M | |
| Diluted EPS | $0.30 | -- | $0.28 | -- | $0.07 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3B | $3.4B | $3.4B | $3.6B | -- | |
| Total Assets | $5.1B | $5.8B | $6B | $6.6B | -- | |
| Current Liabilities | $1.1B | $1.3B | $1.2B | $1.4B | -- | |
| Total Liabilities | $1.2B | $1.4B | $1.4B | $1.6B | -- | |
| Total Equity | $3.9B | $4.4B | $4.6B | $5B | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2022-06-30 | 2023-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.1B | $1B | $652.9M | $644M | $188.4M | |
| Cash From Investing | -$473.7M | -$761.6M | $61.6M | -$862.8M | $157.7M | |
| Cash From Financing | -$408.3M | -$293.9M | -$359.2M | -$114.7M | -$185.8M | |
| Free Cash Flow | $892.2M | $684.5M | $265M | $497.2M | $42.3M | |
CSPCY
Sector
Market Cap
$14.1B
$26M
Price % of 52-Week High
84.73%
51.81%
Dividend Yield
2.49%
0%
Shareholder Yield
5.37%
-1.66%
1-Year Price Total Return
122.52%
-18.29%
Beta (5-Year)
0.532
0.485
Dividend yield:
2.49%
Annualized payout:
$0.15
Payout ratio:
-44.6%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.94
200-day SMA
Buy
Level
$4.21
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$4.66
Relative Strength Index (RSI14)
Buy
Level
64.93
ADX Line
Neutral
Level
0
Williams %R
Sell
Level
-19.7368
50-day SMA
Buy
Level
$4.22
MACD (12, 26)
Buy
Level
0.22
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.0673)
Buy
CA Score
(Annual)
Level (1.3368)
Sell
Beneish M-Score
(Annual)
Level (-1.7977)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-3.3667)
Buy
Piotroski F Score
(Annual)
Level (5)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
CSPC Pharmaceutical Group Ltd. is an investment holding company, which is engaged in the manufacturing and selling of pharmaceutical products. It operates through the following business segments: Finished Drugs, Antibiotics, Vitamin C, Caffeine and Others. The company was founded on August 21, 1997 and is headquartered in Shijiazhuang, China.
Stock Forecast FAQ
In the current month, CSPCY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CSPCY average analyst price target in the past 3 months is --.
-
Where Will CSPC Pharmaceutical Group Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that CSPC Pharmaceutical Group Ltd. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About CSPC Pharmaceutical Group Ltd.?
Analysts are divided on their view about CSPC Pharmaceutical Group Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CSPC Pharmaceutical Group Ltd. is a Sell and believe this share price will rise from its current level to --.
-
What Is CSPC Pharmaceutical Group Ltd.'s Price Target?
The price target for CSPC Pharmaceutical Group Ltd. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CSPCY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for CSPC Pharmaceutical Group Ltd. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CSPCY?
You can purchase shares of CSPC Pharmaceutical Group Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CSPC Pharmaceutical Group Ltd. shares.
-
What Is The CSPC Pharmaceutical Group Ltd. Share Price Today?
CSPC Pharmaceutical Group Ltd. was last trading at $4.94 per share. This represents the most recent stock quote for CSPC Pharmaceutical Group Ltd.. Yesterday, CSPC Pharmaceutical Group Ltd. closed at $4.94 per share.
-
How To Buy CSPC Pharmaceutical Group Ltd. Stock Online?
In order to purchase CSPC Pharmaceutical Group Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CSPCY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CSPCY
Sector
P/E ratio
23.23x
23.85x
PEG ratio
--
-0.01x
P/B ratio
17.31x
1.83x
Price / LTM sales
3.95x
1.56x
Growth Metrics
CSPCY
Sector
Revenue growth
-18.05%
4.18%
Earnings growth
1.3%
9.66%
Revenue (5-year growth)
4.73%
6.28%
Earnings forecast
--
-$0.18
Profitability
CSPCY
Sector
Profitability FY 2024
$2.8B
$3.1M
Return on invested capital
12.94%
-32.89%
Return on assets
9.96%
-29.56%
Return on equity
12.37%
-38.66%
Earnings Date
Last Earnings Date
Nov
20
Next Earnings Date
Apr
2
Estimated Next Earnings Date
Feb
19
Balance Sheet
CSPCY
Sector
Total cash
$1.1B
$25.2M
Short term investments
$201.8M
$25.1M
Total assets
$6.1B
$73M
Long term debt
--
$3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Goldman Sachs Going to Go Up?
Shares of financial giant Goldman Sachs (NYSE:GS) have soared by…
How High Will MSTR Stock Go?
After several months of pressure, shares of Bitcoin treasury Strategy…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
59
RGC alert for Jan 23
Regencell Bioscience Holdings Ltd. [RGC] is up 4.13% over the past day.
Buy
76
HYMC alert for Jan 23
Hycroft Mining Holding Corp. [HYMC] is up 7.58% over the past day.
Sell
24
INSP alert for Jan 23
Inspire Medical Systems, Inc. [INSP] is down 0.57% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
